Recently, post hoc analysis of amatuximab in a trial testing patients with primary diagnosed, unresectable malignant pleural mesothelioma found that patients treated in combination with amatuximab plus cisplatin/pemetrexed standard-of-care tended to show statistical improvement in progression free survival and overall survival in patients with low baseline serum CA125 levels in contrast to those with high levels [18]. This evidence concerns the gene MUC16 and malignant pleural mesothelioma.